In APC R1450X reporter cells treated with gentamicin, PF-4708671 (0.5–20 µM, 24 h) did not enhance nonsense-mutation readthrough. The quantified 20 µM comparison used four independent experiments. This negative result is specific to the tested reporter and combination. [3]
AMPK signaling persists in S6K1/2-deficient fibroblasts
Cell-based study · Wild-type and S6K1/2 double-knockout immortalized mouse embryonic fibroblasts [2]
PF-4708671 increased AMPK Thr172 and ACC Ser79 phosphorylation in both genotypes. S6 phosphorylation also decreased in knockout cells, limiting its specificity as a cellular S6K readout.
Literature-Reported Treatment Conditions
- Treatment concentration
- 3.3, 6.6 and 10 µM
- Method
- Immunoblotting with total AMPK/ACC and tubulin/beta-catenin controls.
- Vehicle
- DMSO
- Co-treatment
- No combination adopted.
- Reported limits
- Exposure duration and independent biological replicate count are not specified in the selected Fig 1 caption or shared Western blot method; duplicate lanes are not treated as independent n. S3 responses are not strictly monotonic.
Methods and source locations
Compound reported in the paper: PF-4708671; Compound label in the paper: PF-4708671
Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.
Fig 1A–B; Figs S1/S3; Methods: Cell culture and Western blot; Results, first paragraph
AMPK Thr172, ACC Ser79 and S6 Ser235/236 and Ser240/244 phosphorylation: Western blot; S3 provides densitometry without biological-n semantics. — Fig 1A–B; S1; S3
Inhibition of mitochondrial complex I
Biochemical assay · Isolated mouse embryonic fibroblast mitochondria [2]
Complex I activity decreased with PF-4708671 concentration. The assayed citrate synthase and other respiratory-enzyme comparisons did not show corresponding inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- Increasing concentrations in Fig 3B; 5 µM PF-4708671 in Fig 3C
- Method
- Rotenone-sensitive NADH–CoQ reductase assay, monitoring NADH oxidation at 340 nm; other enzyme activities measured separately.
- Vehicle
- DMSO
- Co-treatment
- Metformin (5 mM) and rotenone (1 µM) are separate comparators, not combination treatments.
- Reported limits
- Incubation time, independent replicate count and PF concentration for the enzyme panel in Fig 3A are not specified in its caption; no panel-wide quantitative selectivity ratio adopted.
Methods and source locations
Compound reported in the paper: PF-4708671; Compound label in the paper: PF-4708671
Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.
Fig 3A–C; Results, isolated-mitochondria paragraph; Methods: Isolation of Mitochondria and Activity of mitochondrial electron transport components
Mitochondrial complex I enzymatic activity: Reported in Results; visual trend checked in Fig 3B. This is an assay endpoint, not a cellular treatment dose. — Results, isolated-mitochondria paragraph; Fig 3B
No enhancement of gentamicin-mediated reporter readthrough
Cell-based study · APC R1450X nonsense-mutation reporter cell line [3]
Adding PF-4708671 did not enhance gentamicin-mediated nonsense suppression in this reporter model. The quantified comparison at 20 µM was reported as nonsignificant; this does not establish equivalence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5, 1, 5, 10 or 20 µM
- Exposure duration
- 24 h
- Method
- Western blot GFP-BFP readthrough product normalized to GFP; tubulin loading control.
- Vehicle
- DDW for PF-4708671, as reported in Antibodies and reagents.
- Co-treatment
- Gentamicin (GM), 500 µg/ml; GM without PF is the relevant comparator.
- Reported limits
- No exact effect size or P value extracted; official slide thumbnail has limited resolution. Underlying S1 Data not acquired.
Methods and source locations
Compound reported in the paper: PF-4708671; Compound label in the paper: PF-4708671
Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.
S7 Fig and caption; Results: S6K1 negative-result paragraph; Methods: Antibodies and reagents, Western blot and Statistical analysis
GFP-BFP/GFP reporter band-intensity ratio with versus without 20 µM PF-4708671 in GM-treated cells: Western blot densitometry (Fusion-Capt); n semantics taken from S7 caption, not lane count. — S7 Fig, caption and Results S6K1 paragraph